Citations

Clear

3314 citation(s) found for "Do, Alexander".

Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance)
Innocenti, Federico , Sibley, Alexander B. , Patil, Sushant, Etheridge, Amy S. , Jiang, Chen , Ou, Fang‐Shu , Howell, Stefanie , Plummer, Sarah J. , Bertagnolli, Monica M. , McLeod, Howard L. , Auman, J. Todd , Blanke, Charles D. , Furukawa, Yoichi , Kubo, Michiaki , Lenz, Heinz‐Josef , Ratain, Mark J. , Owzar, Kouros , Bertagnolli, Monica M , McLeod, Howard L , Auman, James T , Furukawa, Yoichi , Venook, Alan P , Kubo, Michiaki , Lenz, Heinz-Josef , Parker, Joel S , Ou, Fang-Shu , Casey, Graham , Venook, Alan P. , Parker, Joel S.

Mayo Clinic

Clinical Cancer Research | September 21, 2020 | Volume: 27 | Issue: 1 | Pages: 267-275

10.1158/1078-0432.ccr-20-2021 | PMID 32958699 Get It

Abstract Purpose: Irinotecan/5-fluorouracil (5-FU; FOLFIRI) or oxaliplatin/5-FU (FOLFOX), combined with bevacizumab or cetuximab, are approved, first-line treatments for metastatic colorectal cancer (mCRC). We aimed at identifying germline variants associated with survival in patients with mCRC treated with these regimens in Cancer and Leukemia Group B/SWOG 80405. Experimental Design: Patients with mCRC receiving either FOLFOX or FOLFIRI were randomized to either cetuximab or bevacizumab. DNA from peripheral blood was genotyped for approximately 700,000 SNPs. The association between SNPs and overall survival (OS) was tested in 613 patients of genetically estimated European ancestry using Cox proportional hazards models. Results: The four most significant SNPs associated with OS were three haplotypic SNPs between microsomal glutathione S-transferase 1 (MGST1) and LIM domain only 3 (LMO3, representative HR, 1.56; P = 1.30 × 10−6), and rs11644916 in AXIN1 (HR, 1.39, P = 4.26 × 10−6). AXIN1 is a well-established tumor suppressor gene in colorectal cancer, and rs11644916 (G>A) conferred shorter OS. Median OS for patients with the AA, AG, or GG genotypes was 18.4, 25.6, or 36.4 months, respectively. In 90 patients with stage IV colorectal cancer from The Cancer Genome Atlas (TCGA), rs11649255 in AXIN1 [in almost complete linkage disequilibrium (LD) with rs11644916], was associated with shorter OS (HR, 2.24, P = 0.0096). Using rs11648673 in AXIN1 (in very high LD with rs11644916 and with functional evidence), luciferase activity in three colorectal cancer cell lines was reduced. Conclusions: This is the first large genome-wide association study ever conducted in patients with mCRC treated with first-line standard treatment in a randomized phase III trial. A common SNP in AXIN1 conferred worse OS and the effect was replicated in TCGA. Further studies in colorectal cancer experimental models are required.
Oral Vancomycin, Ursodeoxycholic Acid, or No Therapy for Pediatric Primary Sclerosing Cholangitis: A Matched Analysis
Deneau, Mark , Mack, Cara L. , Mogul, Douglas , Perito, Emily R. , Valentino, Pamela L. , DiGuglielmo, Matthew, Draijer, Laura G. , El‐Matary, Wael , Furuya, Katryn N. , Gupta, Nitika , Hochberg, Jessica T. , Horslen, Simon , Jensen, M. Kyle , Jonas, Maureen M. , Kerkar, Nanda , Koot, Bart G.P. , Laborda, Trevor J., Martínez, Mercedes , Miethke, Alexander , Miloh, Tamir , Ovchinsky, Nadia , Rao, Girish S. , Ricciuto, Amanda , Sathya, Pushpa , Schwarz, Kathleen B. , Shah, Uzma , Vitola, Bernadette , Zizzo, Andréanne N. , Guthery, Stephen L., Deneau, Mark R , Martinez, Mercedes , Mohammad, Saeed , Ricciuto, Amanda , Zizzo, Andréanne , Valentino, Pamela , Amir, Achiya , Lee, Christine Kyuyoung , Loomes, Kathleen M. , Singh, Ruchi

Mayo Clinic

Hepatology | September 18, 2020 | Volume: 73 | Issue: 3 | Pages: 1061-1073

10.1002/hep.31560 | PMID 32946600 Get It

Background and Aims Many children with primary sclerosing cholangitis (PSC) receive oral vancomycin therapy (OVT) or ursodeoxycholic acid (UDCA). There is a paucity of data on whether these medications improve outcomes. Approach and Results We analyzed retrospective data from the Pediatric PSC Consortium. Children treated with OVT were matched 1:1:1 to those treated with UDCA or managed with observation (no treatment) based on the closest propensity score, ensuring similar baseline characteristics. Two hundred sixty‐four patients (88 each with OVT, UDCA, or observation) had matching propensity scores and were similar in demographics, phenotype, immunosuppression, baseline biochemistry, and hepatic fibrosis. After 1 year in an intention‐to‐treat analysis, all outcome metrics were similar regardless of treatment group. In OVT, UDCA, and untreated groups, respectively: Gamma‐glutamyltransferase normalized in 53%, 49%, and 52% (P = not significant [NS]), liver fibrosis stage was improved in 20%, 13%, and 18% and worsened in 11%, 29%, and 18% (P = NS), and the 5‐year probability of liver transplant listing was 21%, 10%, and 12% (P = NS). Favorable outcome was associated with having a mild phenotype of PSC and minimal hepatic fibrosis. Conclusions We presented the largest‐ever description of outcomes on OVT in PSC and compared them to carefully matched patients on UDCA or no therapy. Neither OVT nor UDCA showed improvement in outcomes compared to a strategy of observation. Patients progressed to end‐stage liver disease at similar rates. Spontaneous normalization of biochemistry is common in children receiving no therapy, particularly in the majority of children with a mild phenotype and an early stage of disease. Placebo‐controlled treatment trials are needed to identify effective treatments for pediatric PSC.
Larger Nephron Size and Nephrosclerosis Predict Progressive CKD and Mortality after Radical Nephrectomy for Tumor and Independent of Kidney Function
Đenić, Aleksandar , Elsherbiny, Hisham , Leibovich, Bradley C. , Thompson, R. Houston, Ricaurte, Luisa , Narasimhan, Ramya , Kremers, Walter K. , Alexander, Mariam P., Lerman, Lilach O. , Ricaurte Archila, Luisa, Narasimhan, Ramya , Rule, Andrew D , Denic, Aleksandar , Kremers, Walter K , Mullan, Aidan F. , Lieske, John C. , Rule, Andrew D.

Mayo Clinic

Journal of the American Society of Nephrology | September 16, 2020 | Volume: 31 | Issue: 11 | Pages: 2642-2652

10.1681/asn.2020040449 | PMID 32938650 Get It

Significance Statement Predicting outcomes on the basis of renal histology after a radical nephrectomy has been limited to studies with small sample sizes, short follow-ups, and only a descriptive characterization of histology. In this study of 936 patients followed up for a median of 6.4 years after establishing a new baseline kidney function following radical nephrectomy, the authors used morphometric methods to quantitatively characterize microstructural features on large renal wedge sections. Findings of larger nephrons and more extensive glomerulosclerosis and interstitial fibrosis predicted progressive CKD; interstitial fibrosis also predicted mortality from causes other than cancer. These findings provide insight into the important microstructural features of “generic” CKD in patients without a specific kidney disease and support the use of quantitative methods to evaluate renal histology after a radical nephrectomy to determine patients’ long-term risks. Background Nephron hypertrophy and nephrosclerosis may be important determinants of CKD and mortality. However, studies of outcomes associated with these microstructural features have been limited to small tissue specimens from patients selected for either good kidney health or known kidney disease. Methods To determine whether microstructural features are predictive of progressive CKD and mortality outcomes, we studied patients who underwent a radical nephrectomy for a tumor. Large wedge sections of renal parenchyma distal to the tumor were stained and scanned into high-resolution images; we annotated the cortex and all glomeruli to calculate glomerular volume, cortex volume per glomerulus, and percentage of globally sclerotic glomeruli. Morphometric measurements also included percentages of artery luminal stenosis and interstitial fibrosis/tubular atrophy (IF/TA) of the cortex. At follow-up visits every 6–12 months, we determined which patients experienced progressive CKD (defined as dialysis, kidney transplantation, or a 40% decline from postnephrectomy eGFR). Cox models for these outcomes were adjusted for age, sex, body mass index, hypertension, diabetes, smoking, eGFR, and proteinuria. Results Among 936 patients (mean age, 64 years; postnephrectomy baseline eGFR, 48 ml/min per 1.73 m 2 ), 117 progressive CKD events, 183 noncancer deaths, and 116 cancer deaths occurred during a median follow-up of 6.4 years. Larger glomerular volume, larger cortex per glomerulus, and higher percentage of globally sclerotic glomeruli or IF/TA predicted progressive CKD. Higher percentage IF/TA also predicted noncancer mortality. Microstructural features did not predict cancer mortality or recurrence. Conclusions After a radical nephrectomy, larger nephrons and nephrosclerosis predicted progressive CKD, and IF/TA predicted noncancer mortality. Morphometric analysis of renal parenchyma can predict noncancer clinical events in patients long after their radical nephrectomy.
Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease
Fajgenbaum, David C. , Wu, David , Goodman, Aaron M. , Chadburn, Amy , Srkalović, Gordan , Leitch, Heather A. , Jayanthan, Raj , Schey, Steve , Oksenhendler, Éric , Lechowicz, Mary Jo , Hoffmann, Christian , Pemmaraju, Naveen , Bagg, Adam , Lim, Megan S. , group, the Castleman Disease Collaborative Network Scientific Advisory Board diagnostic criteria international working group and treatment guidelines international working, Wong, Raymond S M , Ferrero, Simone , Dispenzieri, Angela , Zinzani, Pier Luigi , van Rhee, Frits , Fajgenbaum, David C , Lim, Megan S , Wong, Raymond , Nasta, Sunita , Mukherjee, Sudipto , Ferrero, Simone , Sato, Yasuharu , Dispenzieri, Angela , Zinzani, Pier Luigi , Fosså, Alexander , Rhee, Frits van , group, the Castleman Disease Collaborative Network Scientific Advisory Board diagnostic criteria international working group and treatment guidelines international working

Mayo Clinic

American Journal of Hematology | September 16, 2020 | Volume: 95 | Issue: 12 | Pages: 1553-1561

10.1002/ajh.25992 | PMID 32894785 Get It

AbstractIdiopathic multicentric Castleman disease (iMCD) is a rare immunologic disorder characterized by systemic inflammation, multicentric lymphadenopathy, and organ dysfunction. Enlarged lymph nodes demonstrate a spectrum of characteristic but variable histopathologic features historically categorized into hyaline vascular (HV) (or hypervascular [HyperV] more recently), plasmacytic, or “mixed.” Though the etiology is unknown, a pro‐inflammatory cytokine storm, often involving interleukin‐6 (IL‐6), contributes to pathogenesis. Anti‐IL‐6 therapy with siltuximab is the only FDA‐ or EMA‐approved treatment based on efficacy and safety in multiple studies. Importantly, no patients considered to have HV histopathology achieved the primary endpoint in the Phase II study. NCCN currently recommends siltuximab first‐line for iMCD, except for patients considered to have HV histopathology. We investigated whether histopathologic subtype should guide siltuximab treatment decisions. Secondary analyses of clinical trial and real‐world data revealed similar clinical benefit across histopathologic subtypes. Notably, only 18 of 79 patients in the Phase II study were consistently classified into histopathologic subtype by three independent review panels, demonstrating limited reliability to guide treatment decisions. Real‐world data further demonstrate siltuximab's effectiveness in patients considered to have HV (or HyperV). Though histopathology is a critical component for diagnosis, there is insufficient evidence to guide treatment based solely on lymph node histopathologic subtype.
Keloids: a review of therapeutic management
Ekstein, Samuel F. , Wyles, Saranya P. , Moran, Steven L. , Meves, Alexander

Mayo Clinic

International Journal of Dermatology | September 16, 2020 | Volume: 60 | Issue: 6 | Pages: 661-671

10.1111/ijd.15159 | PMID 32905614 Get It

Abstract Keloid scar formation arises from a disorganized fibroproliferative collagen response that extends beyond the original wound margins because of excessive production of extracellular matrix (ECM). Despite treatment options for keloid scars including medical and surgical therapies, such as intralesional steroid injection and surgical excision, the recurrence rate remains high. Herein we consolidate recently published narrative reviews, systematic reviews, and meta‐analyses to provide an overview of updated treatment recommendations for keloidal scar formation. PubMed search engine was used to access the MEDLINE database to investigate updates regarding keloid incidence and treatment. More than 100 articles were reviewed. Keloid management remains a multimodal approach. There continues to be no gold standard of treatment that provides a consistently low recurrence rate; however, the increasing number of available treatments and synergistic combinations of these treatments (i.e., laser‐based devices in combination with intralesional steroids, or 5‐fluorouracil (5‐FU) in combination with steroid therapy) is showing favorable results. Future studies could target the efficacy of novel treatment modalities (i.e., autologous fat grafting or stem cell‐based therapies) for keloid management. This review article provides updated treatment guidelines for keloids and discusses insight into management to assist patient‐focused, evidence‐based clinical decision making.
8q24 Clear Cell Renal Cell Carcinoma Germline Variant is Associated with VHL Mutation Status and Clinical Aggressiveness
Eckel‐Passow, Jeanette E. , Yan, Huihuang , Kosel, Matthew, Serie, Daniel, Jenkins, Robert B. , Costello, Brian A. , Leibovich, Bradley C. , Parker, Alexander S. , Ho, Thai H.

Mayo Clinic

No container title available | September 14, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-48012/v2 Get It

Abstract Background The four most commonly-mutated genes in clear cell renal cell carcinoma (ccRCC) tumors are BAP1 , PBRM1 , SETD2 and VHL . And, there are currently 14 known RCC germline variants that have been reproducibly shown to be associated with RCC risk. However, the association of germline genetics with tumor genetics and clinical aggressiveness are unknown. Methods We analyzed 420 ccRCC patients from The Cancer Genome Atlas (TCGA). Molecular subtype was determined based on acquired mutations in BAP1 , PBRM1 , SETD2 and VHL . Aggressive subtype was defined clinically using Mayo SSIGN score and molecularly using the ccA/ccB gene expression subtype. Publically-available Hi-C data were used to link germline risk variants with candidate target genes. Results The 8q24 variant rs35252396 was significantly associated with VHL mutation status (OR=1.6, p=0.0037) and SSIGN score (OR=1.9, p=0.00094), after adjusting for multiple comparisons. We observed that, while some germline variants have interactions with nearby genes, some variants demonstrate long-range interactions with target genes. Conclusions These data further demonstrate the link between rs35252396, HIF pathway and ccRCC clinical aggressiveness, providing a more comprehensive picture of how germline genetics and tumor genetics interact with respect to tumor development and progression.
Genomic and Epigenomic Landscaping Defines New Therapeutic Targets for Adenosquamous Carcinoma of the Pancreas
Lenkiewicz, Elizabeth, Malasi, Smriti, Hogenson, Tara L. , Flores, Luis F. , Barham, Whitney , Phillips, William J. , Roesler, Alexander S. , Chambers, Kendall R. , Rajbhandari, Nirakar , Antal, Corina E. , Downes, Michael , Cridebring, Derek , Xiong, Yuning, Lee, Jeong‐Heon , Ye, Zhenqing , Yan, Huihuang , Leiting, Jennifer L. , Evans, Ronald M. , Ördög, Tamás , Truty, Mark J. , Reya, Tannishtha , Hoff, Daniel D. Von , Fernández-Zapico, Martín E. , Barrett, Michael T. , Phillips, William J. , Grandgenett, Paul M , Hernandez, Matthew C , Leiting, Jennifer L , Ordog, Tamas , Von Hoff, Daniel D , Lee, Jeong-Heon , Evans, Ronald M , Hayashi, Akimasa , Grandgenett, Paul M. , Hollingsworth, Michael A. , Hernandez, Matthew C. , Borad, Mitesh J. , Phillips, William J.

Mayo Clinic

Cancer Research | September 14, 2020 | Volume: 80 | Issue: 20 | Pages: 4324-4334

10.1158/0008-5472.can-20-0078 | PMID 32928922 Get It

Abstract Adenosquamous cancer of the pancreas (ASCP) is a subtype of pancreatic cancer that has a worse prognosis and greater metastatic potential than the more common pancreatic ductal adenocarcinoma (PDAC) subtype. To distinguish the genomic landscape of ASCP and identify actionable targets for this lethal cancer, we applied DNA content flow cytometry to a series of 15 tumor samples including five patient-derived xenografts (PDX). We interrogated purified sorted tumor fractions from these samples with whole-genome copy-number variant (CNV), whole-exome sequencing, and Assay for Transposase-Accessible Chromatin using sequencing (ATAC-seq) analyses. These identified a variety of somatic genomic lesions targeting chromatin regulators in ASCP genomes that were superimposed on well-characterized genomic lesions including mutations in TP53 (87%) and KRAS (73%), amplification of MYC (47%), and homozygous deletion of CDKN2A (40%) that are common in PDACs. Furthermore, a comparison of ATAC-seq profiles of three ASCP and three PDAC genomes using flow-sorted PDX models identified genes with accessible chromatin unique to the ASCP genomes, including the lysine methyltransferase SMYD2 and the pancreatic cancer stem cell regulator RORC in all three ASCPs, and a FGFR1-ERLIN2 fusion associated with focal CNVs in both genes in a single ASCP. Finally, we demonstrate significant activity of a pan FGFR inhibitor against organoids derived from the FGFR1-ERLIN2 fusion–positive ASCP PDX model. Our results suggest that the genomic and epigenomic landscape of ASCP provide new strategies for targeting this aggressive subtype of pancreatic cancer. Significance: These data provide a unique description of the ASCP genomic and epigenomic landscape and identify candidate therapeutic targets for this dismal cancer.
Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine
Gerotziafas, Grigoris , Catalano, Mariella, Pécsvárady, Zsolt, Wautrecht, Jean Claude, Olinic, Dan-Mircea , Farkas, Katalin , Elalamy, Ismaı̈l , Fareed, Jawed , Papageorgiou, Chryssa, Arellano, Rosella S., Agathagelou, Petros, Antic, Darco, Auad, Luciana, Banfić, Ljiljana , Bartolomew, John R., Benczúr, Béla , Bernardo, M., Boccardo, Francesco M., Cifkova, Renate, Marchi, Sergio De , Dimakakos, Evangelos , Dimitrov, Gabriel, Edmonds, Michael , Nazar, Essam Abo El, Erer, Dilek , Esponda, Omar L. , Gschwandtner, Michael E., Gu, Yongquan , Heinzmann, Mónica, Hamadé, A. , Jatoi, Noor-Ahmed, Karahan, Oğuz , Karplus, Thomas E., Klein‐Weigel, Peter, Kolossváry, Endre , Kozak, Matija, Lefkou, Eleftheria , Lessiani, Gianfranco , Marcoccia, Antonella , Marshang, Peter, Marakomichelakis, George , Matuška, Jiří , Moraglia, Luc, Pillon, Sergio , Poredoš, Pavel , Salvador, David Raymund K., Schlager, Oliver , Schernthaner, G. , Sieron, Alexander, Spaak, Jonas , Spyropoulos, Alex C. , Stanek, Agata , Štvrtinová, Viera, Tafur, Alfonso , Dreden, Patrick Van , Vardas, Panagiotis E., Vasić, Dragan , Wennberg, Paul W. , Zhai, Zhenguo , Committee, Scientific Reviewer, Catalano, M. , Gerotziafas, Grigoris T , Wennberg, Paul, Catalano, Mariella , Dimakakos, Evangelos , Farkas, Katalin , Stanek, Agata , Colgan, Mary Paula , Fazeli, Bahare , Falanga, Anna , Cosmi, Benilde , Dimopoulos, Meletios Α. , Durand‐Zaleski, Isabelle , Gresele, Paolo , Hamburg, Naomi M. , Karetová, Debora , Liew, Aaron , Marschang, Peter , Prior, Manlio , Sprynger, Muriel , Šuput, Dušan , Szuba, Andrzej , Vardas, Panagiotis E., Vikkula, Miikka , Committee, Scientific Reviewer

Mayo Clinic

Thrombosis and Haemostasis | September 13, 2020 | Volume: 120 | Issue: 12 | Pages: 1597-1628

10.1055/s-0040-1715798 | PMID 32920811 Get It

AbstractCOVID-19 is also manifested with hypercoagulability, pulmonary intravascular coagulation, microangiopathy, and venous thromboembolism (VTE) or arterial thrombosis. Predisposing risk factors to severe COVID-19 are male sex, underlying cardiovascular disease, or cardiovascular risk factors including noncontrolled diabetes mellitus or arterial hypertension, obesity, and advanced age. The VAS-European Independent Foundation in Angiology/Vascular Medicine draws attention to patients with vascular disease (VD) and presents an integral strategy for the management of patients with VD or cardiovascular risk factors (VD-CVR) and COVID-19. VAS recommends (1) a COVID-19-oriented primary health care network for patients with VD-CVR for identification of patients with VD-CVR in the community and patients' education for disease symptoms, use of eHealth technology, adherence to the antithrombotic and vascular regulating treatments, and (2) close medical follow-up for efficacious control of VD progression and prompt application of physical and social distancing measures in case of new epidemic waves. For patients with VD-CVR who receive home treatment for COVID-19, VAS recommends assessment for (1) disease worsening risk and prioritized hospitalization of those at high risk and (2) VTE risk assessment and thromboprophylaxis with rivaroxaban, betrixaban, or low-molecular-weight heparin (LMWH) for those at high risk. For hospitalized patients with VD-CVR and COVID-19, VAS recommends (1) routine thromboprophylaxis with weight-adjusted intermediate doses of LMWH (unless contraindication); (2) LMWH as the drug of choice over unfractionated heparin or direct oral anticoagulants for the treatment of VTE or hypercoagulability; (3) careful evaluation of the risk for disease worsening and prompt application of targeted antiviral or convalescence treatments; (4) monitoring of D-dimer for optimization of the antithrombotic treatment; and (5) evaluation of the risk of VTE before hospital discharge using the IMPROVE-D-dimer score and prolonged post-discharge thromboprophylaxis with rivaroxaban, betrixaban, or LMWH.
Teaching NeuroImages: Neuroimaging in Adult-Onset Alexander Disease
Gopal, Neethu , Gupta, Vivek , Williams, Lindsy N., Sandhu, Sukhwinder J.S. , Sandhu, Sukhwinder S

Mayo Clinic

Neurology | September 12, 2020 | Volume: 96 | Issue: 5 | Pages: No page available

10.1212/wnl.0000000000010803 | PMID 32917798 Get It

Cardio‐oncology care in the era of the coronavirus disease 2019 (COVID‐19) pandemic: An International Cardio‐Oncology Society (ICOS) statement
Carver, Joseph R. , Porter, Charles , Liu, Jennifer E. , Mitchell, Joshua D. , Fradley, Michael G. , Pusic, Iskra , Stockerl‐Goldstein, Keith , Ganatra, Sarju , O’Quinn, Rupal , Minotti, Giorgio , Szmit, Sebastian , Alvarez‐Cardona, Jose, Curigliano, Giuseppe , Neilan, Tomas G. , Herrmann, Joerg , Herrmann, Joerg , Curigliano, Giuseppe , Mitchell, Joshua D , Minotti, Giorgio , Lenihan, Daniel , Dent, Susan , Thavendiranathan, Paaladinesh , Nohria, Anju , Blaes, Anne , Lyon, Alexander R. , López‐Fernández, Teresa , Cardinale, Daniela , Stockerl-Goldstein, Keith

Mayo Clinic

CA: A Cancer Journal for Clinicians | September 11, 2020 | Volume: 70 | Issue: 6 | Pages: 480-504

10.3322/caac.21635 | PMID 32910493 Get It

Abstract The severe acute respiratory syndrome coronavirus 2 (SARS–CoV‐2) has given rise to a pandemic of unprecedented proportions in the modern era because of its highly contagious nature and impact on human health and society: coronavirus disease 2019 (COVID‐19). Patients with cardiovascular (CV) risk factors and established CV disease (CVD) are among those initially identified at the highest risk for serious complications, including death. Subsequent studies have pointed out that patients with cancer are also at high risk for a critical disease course. Therefore, the most vulnerable patients are seemingly those with both cancer and CVD, and a careful, unified approach in the evaluation and management of this patient population is especially needed in times of the COVID‐19 pandemic. This review provides an overview of the unique implications of the viral outbreak for the field of cardio‐oncology and outlines key modifications in the approach to this ever‐increasing patient population. These modifications include a shift toward greater utilization of cardiac biomarkers and a more focused CV imaging approach in the broader context of modifications to typical practice pathways. The goal of this strategic adjustment is to minimize the risk of SARS–CoV‐2 infection (or other future viral outbreaks) while not becoming negligent of CVD and its important impact on the overall outcomes of patients who are being treated for cancer.